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Background:  A  blue  letter  (safety advisory)  for dabigatran  was  issued  by the  Japanese  Ministry  of  Health,
Labour  and  Welfare  in August  2011.  Changes  in  physicians’  attitudes  toward  dabigatran  use  before  and
after  the blue  letter  have  not  been  previously  reported.
Methods and  results:  Between  March  2011  and  July 2012,  dabigatran  was  prescribed  to  404  Japanese
patients  with  nonvalvular  atrial ﬁbrillation  at The  Cardiovascular  Institute  (Tokyo,  Japan).  Patients
were  divided  into  three  groups  according  to  the ﬁrst prescription  date: phase  I (before  the  blue  let-
ter,  n =  135);  phase  II (after  the  blue  letter  and  before  permission  for  longer-term  prescriptions,  n  =  112);
and  phase  III  (after  permission  for  longer-term  prescriptions,  n = 157).  In  phase  II, dabigatran  use  tended
to  be avoided  for patients  with  older  age,  renal  dysfunction,  receiving  antiplatelet  medication,  or  p-
glycoprotein  inhibitors.  Measurement  of  activated  partial  thromboplastin  time  signiﬁcantly  increased
from  phase  I to  III. In phase  III,  the tendencies  seen  in  phase  II were  reversed:  dabigatran  use in  patients
with  older  age and  renal  dysfunction  tended  to increase,  but decreased  or remained  the  same  in patients
receiving  antiplatelet  medications  or  p-glycoprotein  inhibitors.
Conclusions:  We  described  the  changes  in the attitudes  of attending  physicians  toward  dabigatran  pre-
scription  after  the  blue  letter  in  a  specialized  hospital  for cardiovascular  care  in Japan,  which,  we
believe,  involve  useful  information  for safe  use  of  dabigatran  in  a real-world  clinical  setting.  How-
ffect  
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Anticoagulation is one of the most signiﬁcant factors in stroke
revention in patients with atrial ﬁbrillation (AF) in both Western
ountries [1,2] and Japan [3–6]. Dabigatran, an oral anticoagulant,
as approved and launched in Japan in late March 2011 and cur-
ently, at least 140 000 patients are taking it each month. Before
he launch, dabigatran was expected to be a safe, monitoring-free
rug that could replace warfarin and be used even in high-risk or
he most aged patients with AF, for whom warfarin use had been
∗ Corresponding author at: Department of Cardiovascular Medicine, The Cardio-
ascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo 106-0031, Japan.
el.: +81 3 3408 2151; fax: +81 3 3408 2159.
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914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.05.016of the  blue  letter  should  be  ascertained  in a nationwide,  multicenter
anese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
avoided. However, a considerable number of patients with severe
bleeding were reported in a blue letter (safety advisory) issued by
the Ministry of Health, Labour and Welfare in August 2011 [7].
The cases of severe bleeding described in the blue letter involved a
dabigatran overdose or contraindication regarding renal function.
Similar safety alarms have been observed in other countries [8–14]
and many discussions have occurred regarding the indications for
dabigatran use and the necessity of monitoring patients who  are
taking dabigatran [15–21].
Irrespective of the many discussions, the responses of attending
physicians to the blue letter in real-world clinical practice have
not been previously reported. Although we  previously reported
our experience with dabigatran use, the data did not distinguish
between the time before and after the blue letter [22]. We  report
the changes in physicians’ attitudes toward dabigatran use before
vier Ltd. All rights reserved.
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nd after the blue letter through a single-center experience of 404
atients with nonvalvular AF under dabigatran therapy at The Car-
iovascular Institute of Tokyo, Japan.
ethods
ata collection
Dabigatran was prescribed for the ﬁrst time on 25 March 2011
t The Cardiovascular Institute. Clinical data from 404 consecu-
ive patients with nonvalvular AF under dabigatran therapy were
ubsequently collected by 31 July 2012. We  recorded the status of
hese patients, including patient background; creatinine clearance
ate (CCr); activated partial thromboplastin time (aPTT; normal
ange, 25–35 s); the criteria for initiation of dabigatran; and the
ncidence rates of adverse events (side effects, discontinuation, and
hromboembolic events). Side effects included epigastric symp-
oms, diarrhea, and major and minor bleeding. Major bleeding
as deﬁned as bleeding events requiring hospital admission and
ther types of bleeding were deﬁned as minor bleeding. These
dverse events occurred during follow up between March 2011 and
ovember 2012.
thics
The ethical committee of The Cardiovascular Institute approved
his study, which was performed in accordance with the Declara-
ion of Helsinki.
tatistical methods
All study patients (n = 404) were divided into three groups
ccording to the date of the ﬁrst prescription of dabigatran in our
ospital: phase I (before the blue letter, n = 135); phase II (after
he blue letter and before permission for longer-term prescriptions,
 = 112); and phase III (after permission for longer-term prescrip-
ions, n = 157).
Categorical and consecutive data are presented as number
%) and mean ± standard deviation, respectively. In addition, the
ercentages of adverse events (side effects, discontinuation, and
hromboembolic events) are presented as ratios of the number of
vents and patients. The chi-square test and unpaired t-test were
sed for group comparisons. The CCr at the initiation of dabiga-
ran therapy and the aPTT in the morning and afternoon at the
able 1
atient characteristics and co-morbidities with dabigatran therapy in patients with nonv
Characteristics Total
N = 404
Phase I
n  = 135
Age (years) 66.0 ± 11.9 67.5 ± 11.9
Body  weight (kg) 67.2 ± 13.5 66.6 ± 14.7
Men,  n (%) 306 (75.7) 97 (71.9) 
AF  type
First-detected, n (%) 47 (11.6) 8 (5.9) 
Paroxysmal, n (%) 193 (47.8) 63 (46.7) 
Persistent, n (%) 65 (16.1) 20 (14.8) 
Permanent, n (%) 99 (24.5) 44 (32.6) 
Attending physician (all, cardiologist)
Arrhythmia specialist, n (%) 285 (70.5) 105 (77.8) 
Non-arrhythmia specialist, n (%) 119 (29.5) 30 (22.2) 
Heart  failure, n (%) 47 (11.6) 22 (16.3) 
Valvular disease, n (%) 29 (7.2) 12 (8.9) 
Ischemic heart disease, n (%) 28 (6.9) 13 (9.6) 
Cardiomyopathy, n (%) 27 (6.7) 11 (8.1) 
Hypertension, n (%) 202 (50.0) 71 (52.6) 
Diabetes mellitus, n (%) 54 (13.4) 18 (13.3) 
Chronic kidney disease, n (%) 164 (40.6) 56 (41.5) 
History of stroke and TIA, n (%) 20 (5.0) 6 (4.4) 
ategorical and consecutive data are presented as number (%) and mean ± standard devia
F,  atrial ﬁbrillation; TIA, transient ischemic attack.ology 62 (2013) 366–373 367
outpatient clinics are presented using bar graphs grouped by dif-
ferent time periods. Statistical analyses were performed using SPSS
for Windows software, version 19.0 (SPSS, Inc., Chicago, IL, USA).
Statistical signiﬁcance was set at a two-sided p-value of <0.05.
Results
Differences in patient characteristics
Patient characteristics are summarized in Table 1. Dabigatran
was prescribed for 135, 112 and 157 patients in phases I, II, and III,
respectively. Patients in phase I (before the blue letter) comprised
32.6% of patients with permanent AF, which decreased to 10.7%
in phase II (after the blue letter but before permission for longer-
term prescriptions). Similarly, patients with heart failure receiving
dabigatran decreased from 16.3% in phase I to 6.3% in phase II. In
contrast, in phase III (after permission for longer-term prescrip-
tions), the ﬁndings were reversed. Dabigatran use in the presence
of permanent AF and heart failure increased to 27.4% and 11.5%
in phase III, respectively. Notably, prescription by non-arrhythmia
specialists increased signiﬁcantly in phase III.
The distributions of thromboembolic risk scoring systems are
displayed in Table 2. Throughout phases I–III, the distribution of
the CHADS2 and CHA2DS2-VASc scores did not change signiﬁcantly,
although patients in phase II tended to have a lower risk compared
with patients in phases I and III.
The sampling rates and distribution of CCr are shown in Fig. 1.
The CCr was  checked at the start of dabigatran therapy in more
than 95% of the patients in each phase (Fig. 1A). The distribution
of the CCr at the outpatient clinic is shown in Fig. 1B. In phases
I and III, patients with a reduced CCr (<50 ml/min) accounted for
approximately 15% of those prescribed dabigatran, but accounted
for only approximately 5% in phase II.
Differences in medications
Information regarding concurrent medications and dabigatran
dose are shown in Table 3. A reduced dose (220 mg/day) was
used in 63.0% and 63.4% of patients in phases I and II, respec-
tively, which increased signiﬁcantly to 78.3% of patients in phase III
(p = 0.006). Co-administration of p-glycoprotein inhibitors consis-
tently decreased from 17.0% in phase I to 8.9% and 3.8% in phases II
and III, respectively (p < 0.001). In addition, the use of aspirin tended
alvular atrial ﬁbrillation.
Phase II
n  = 112
Phase III
n = 157
p-Value
 64.3 ± 11.2 66.0 ± 12.2 0.102
 68.8 ± 13.0 66.7 ± 12.7 0.377
86 (76.8) 123 (78.3) 0.415
23 (20.5) 16 (10.2) <0.001
50 (44.6) 80 (51.0)
27 (24.1) 18 (11.5)
12 (10.7) 43 (27.4)
91 (81.3) 89 (56.7) <0.001
21 (18.8) 68 (43.3)
7 (6.3) 18 (11.5) 0.049
4 (3.6) 13 (8.3) 0.216
6 (5.4) 9 (5.7) 0.316
5 (4.5) 11 (7.0) 0.503
52 (46.4) 79 (50.3) 0.625
20 (17.9) 16 (10.2) 0.190
46 (41.1) 62 (39.5) 0.935
5 (4.5) 9 (5.7) 0.846
tion, respectively.
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Table 2
Distribution of CHADS2 and CHA2DS2-VASc scores in patients with nonvalvular atrial ﬁbrillation under dabigatran therapy.
Total
N = 404
Phase I
n = 135
Phase II
n = 112
Phase III
n = 157
p-Value
CHADS2 score
Mean ± SD 1.1 ± 1.1 1.2 ± 1.2 1.0 ± 1.0 1.1 ± 1.0 0.349
≥2,  n (%) 115 (28.5) 39 (28.9) 31 (27.7) 45 (28.7) 0.976
Distribution, n (%) 0.049
0  138 (34.2) 41 (30.4) 43 (38.4) 54 (34.4)
1  151 (37.4) 55 (40.7) 38 (33.9) 58 (36.9)
2  76 (18.8) 24 (17.8) 21 (18.8) 31 (19.7)
3  26 (6.4) 7 (5.2) 8 (7.1) 11 (7.0)
4  8 (2.0) 4 (3.0) 2 (1.8) 2 (1.3)
5  4 (1.0) 3 (2.2) 0 (0.0) 1 (0.6)
6  1 (0.2) 1 (0.7) 0 (0.0) 0 (0.0)
CHA2DS2-VASc score
Mean ± SD 2.0 ± 1.5 2.2 ± 1.6 1.8 ± 1.5 1.9 ± 1.4 0.075
≥2,  n (%) 236 (58.4) 87 (64.4) 61 (54.5) 88 (56.1) 0.212
Distribution, n (%) 0.080
0  72 (17.8) 17 (12.6) 31 (27.7) 24 (15.3)
1  96 (23.8) 31 (23.0) 20 (17.9) 45 (28.7)
2  107 (26.5) 40 (29.6) 27 (24.1) 40 (25.5)
3  68 (16.8) 24 (17.8) 20 (17.9) 24 (15.3)
4  37 (9.2) 12 (8.9) 8 (7.1) 17 (10.8)
5  16 (4.0) 5 (3.7) 6 (5.4) 5 (3.2)
6  5 (1.2) 4 (3.0) 0 (0.0) 1 (0.6)
7  3 (0.7) 2 (1.5) 0 (0.0) 1 (0.6)
8  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
9  0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
C  devia
S
t
i
D
m
a
d
3
p
sategorical and consecutive data are presented as number (%) and mean ± standard
D,  standard deviation.
o decrease from 17.0% in phase I to 10.7% in phase II and to 11.5%
n phase III (p = 0.251).
ifferences in indications for starting dabigatran and
easurement of aPTT
Information regarding indications for starting dabigatran ther-
py is shown in Table 4. In phases I and III, the conditions for starting
abigatran were similar: dabigatran replaced warfarin in 43.0% and
3.1% of patients, and was newly started in 52.6% and 53.5% of
atients, respectively. In contrast, in phase II, dabigatran was newly
tarted in a signiﬁcantly high number of patients (81.3%, p < 0.001).
Fig. 1. Differences in sampling rates and distribution of the creatinine clearantion, respectively.
The distribution of patients with a CHADS2 score of 0 points con-
sistently exceeded 30% throughout the three phases: 30.4%, 38.4%,
and 34.4% in phases I, II, and III, respectively. In these patients, the
indication for starting dabigatran differed between phase II and
the others: in phase II, temporary use for an invasive procedure,
including catheter ablation or cardioversion, was the most preva-
lent indication, while in phases I and III, a CHA2DS2-VASc score
of ≥1 (mostly in patients aged ≥65 years) was  the most prevalent
indication.The sampling rates and distribution of aPTT are shown in Fig. 2.
Within 3 months after starting dabigatran, aPTT was  measured in
67.4% of patients in phase I, and the blood-sampling rate increased
thereafter to 78.6% and 90.4% in phases II and III, respectively
ce rate (CCr) at the start of dabigatran therapy among the three phases.
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Table  3
Concurrent medications and dabigatran dose in patients with nonvalvular atrial ﬁbrillation under dabigatran therapy.
Total
N = 404
Phase I
n = 135
Phase II
n = 112
Phase III
n = 157
p-Value
Customary dose (300 mg/day), n (%) 125 (30.9) 50 (37.0) 41 (36.6) 34 (21.7) 0.006
Reduced dose (220 mg/day), n (%) 279 (69.1) 85 (63.0) 71 (63.4) 123 (78.3)
Criteria for reduced dose, n (%)
Age ≥70 years, n (%) 172 (42.6) 66 (48.9) 38 (33.9) 68 (43.3) 0.059
Creatinine clearance rate <50 ml/min, n (%) 50 (12.4) 19 (14.1) 8 (7.1) 23 (14.6) 0.140
Use  of p-glycoprotein inhibitors, n (%) 39 (9.7) 23 (17.0) 10 (8.9) 6 (3.8) <0.001
Use  of antiplatelet medication 53 (13.1) 23 (17.0) 12 (10.7) 18 (11.5) 0.251
History of hemorrhagic disease, n (%) 17 (4.2) 7 (5.2) 6 (5.4) 4 (2.5) 0.415
History of intracranial bleeding, n (%) 7 (1.7) 3 (2.2) 2 (1.8) 2 (1.3) 0.824
History of major bleeding, n (%) 1 (0.2) 1 (0.7) 0 (0.0) 0 (0.0) 0.368
≥2  criteria for reduced dose, n (%) 90 (22.3) 43 (31.9) 16 (14.3) 31 (19.7) 0.003
Use  of antiarrhythmic drugs
Type I, n (%) 118 (29.2) 30 (22.2) 40 (35.7) 48 (30.6) 0.060
Type  II, n (%) 131 (32.4) 44 (32.6) 35 (31.3) 52 (33.1) 0.948
Type  III, n (%) 12 (3.0) 5 (3.7) 2 (1.8) 5 (3.2) 0.663
Amiodarone, n (%) 6 (1.5) 3 (2.2) 2 (1.8) 1 (0.6) 0.511
Type  IV, n (%) 51 (12.6) 24 (17.8) 13 (11.6) 14 (8.9)a 0.070
Verapamil, n (%) 33 (8.2) 20 (14.8) 8 (7.1) 5 (3.2) 0.001
Diltiazem, n (%) 17 (4.2) 4 (3.0) 4 (3.6) 9 (5.7) 0.464
Bepridil, n (%) 2 (0.5) 0 (0.0) 1 (0.9) 1 (0.6) 0.578
Digitalis, n (%) 30 (7.4) 11 (8.1) 6 (5.4) 13 (8.3) 0.617
Other  drugs
Gastric-coating agents, n (%) 26 (0.1) 13 (9.6) 3 (2.7) 10 (6.4) 0.086
H2-blockers, n (%) 30 (7.4) 13 (9.6) 7 (6.3) 10 (6.4) 0.488
Proton-pump inhibitors, n (%) 56 (13.9) 15 (11.1) 11 (9.8) 30 (19.1) 0.050
RAS  inhibitors, n (%) 117 (29.0) 38 (28.1) 32 (28.6) 47 (29.9) 0.940
Statins, n (%) 61 (15.1) 20 (14.8) 14 (12.5) 27 (17.2) 0.566
Loop  diuretics, n (%) 44 (0.1) 18 (13.3) 8 (7.1) 18 (11.5) 0.286
Thiazide diuretics, n (%) 9 (2.2) 2 (1.5) 1 (0.9) 6 (3.8) 0.213
C  devia
(
p
p
t
i
o
r
P
N
1
T
I
Categorical and consecutive data are presented as number (%) and mean ± standard
a Among 14 patients, 1 patient received both diltiazem and bepridil.
p < 0.001). The sampling rates increased in patients with a longer
eriod of dabigatran use (≥90 days): 82.9%, 94.2%, and 98.9% in
hases I, II, and III, respectively (p < 0.001, Fig. 2A). The distribu-
ion of aPTT at the outpatient clinic in the morning and afternoon
s shown in Fig. 2B. In each phase, a high aPTT value (≥70 s) was
bserved in approximately 5% of patients in the morning but was
arely observed in the afternoon.
atient outcomesDuring the observation period (between March 2011 and
ovember 2012; 254.9 ± 245.7 days, 156.5 ± 141.6 days, and
21.4 ± 80.6 days, in phases I, II, and III, respectively), one
able 4
ndications for starting dabigatran therapy.
Total
N = 404
P
n
History of oral anticoagulation
Newly started 246 (60.9) 7
Continued from previous physician 33 (8.2) 
Change from warfarin 123 (30.4) 5
Change from rivaroxaban 1 (0.2) 
CHADS2 score 
≥2,  n (%) 115 (28.5) 3
1,  n (%) 151 (37.4) 5
0,  n (%) 138 (34.2) 4
Indications irrespective of CHADS2 0 point
CHA2DS2-VASc score of ≥1, n (%) 66 (16.3) 2
Age  of 65–74 years, n (%) 52 (12.9) 1
Thrombosis or contrast echo in left atrium, n (%) 2 (1.4) 
Temporary use, n (%) 66 (16.3) 1
Scheduled catheter ablation, n (%) 52 (12.9) 
Before chemical cardioversion, n (%) 6 (1.5) 
Before electrical cardioversion, n (%) 15 (3.7) 
ategorical and consecutive data are presented as number (%) and mean ± standard deviation, respectively.
thromboembolic event (ischemic stroke) occurred in a patient
in phase I and one major bleeding event from a rectal ulcer
occurred in a patient in phase III. Side effects occurred in 12.6%,
12.5%, and 13.4% of patients in phases I, II, and III, respectively,
but signiﬁcant changes were not observed (p = 0.974). Epigastric
symptoms were consistently the major adverse events in each
phase (8.9%, 8.0%, and 8.9% in phases I, II, and III, respectively)
(Table 5).
Discontinuation of dabigatran occurred in 42.2%, 51.8%, and
35.0% of patients in phases I, II, and III, respectively (Table 6). Sched-
uled discontinuation of temporary use comprised 26.7% on average,
and was  noticeably higher in phase II (42.9%). In contrast, discon-
tinuation with unexpected problems occurred in 14.6% on average,
hase I
 = 135
Phase II
n = 112
Phase III
n = 157
p-Value
1 (52.6) 91 (81.3) 84 (53.5) <0.001
6 (4.4) 8 (7.1) 19 (12.1) 0.053
8 (43.0) 13 (11.6) 52 (33.1) <0.001
0 (0.0) 0 (0.0) 1 (0.6) 0.454
0.742
9 (28.9) 31 (27.7) 45 (28.7)
5 (40.7) 38 (33.9) 58 (36.9)
1 (30.4) 43 (38.4) 54 (34.4)
4 (17.8) 12 (10.7) 30 (19.1) 0.007
9 (14.1) 8 (7.1) 25 (15.9) 0.008
1 (2.4) 0 (0.0) 1 (1.9) 0.614
2 (8.9) 30 (26.8) 24 (15.3) <0.001
7 (5.2) 25 (22.3) 20 (12.7) <0.001
1 (0.7) 3 (2.7) 2 (1.3) 0.569
4 (3.0) 8 (7.1) 3 (1.9) 0.118
tion, respectively.
370 S. Suzuki et al. / Journal of Cardiology 62 (2013) 366–373
Fig. 2. Differences in sampling rates and distribution of activated partial thromboplastin time (aPTT) under dabigatran therapy among the three phases.
Table 5
Side effects and adverse events.
Total
N = 404
Phase I
n = 135
Phase II
n = 112
Phase III
n = 157
p-Value
Thromboembolic events 1 (0.2) 1 (0.7) 0 (0.0) 0 (0.0) 0.368
Incidence of side effects 52 (12.9) 17 (12.6) 14 (12.5) 21 (13.4) 0.971
Epigastric symptoms 35 (8.7) 12 (8.9) 9 (8.0) 14 (8.9) 0.962
Diarrhea 5 (1.2) 3 (2.2) 0 (0.0) 2 (1.3) 0.290
Intracranial bleeding 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) –
Major bleeding (excluding intracranial bleeding) 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.6) 0.454
Minor bleeding 16 (4.0) 5 (3.7) 6 (5.4) 5 (3.2) 0.655
Percentages of adverse events (thromboembolic events and side effects) are presented as ratios of the number of events and patients.
Table 6
Discontinuation.
Total
N = 404
Phase I
n  = 135
Phase II
n = 112
Phase III
n = 157
p-Value
Discontinuation, n (%) 170 (42.1) 57 (42.2) 58 (51.8) 55 (35.0) 0.023
With  unexpected problems, n (%) 59 (14.6) 25 (18.5) 9 (8.0) 25 (15.9) 0.056
Side  effects, n (%) 31 (7.7) 15 (11.1) 3 (2.7) 13 (8.3) 0.043
Decline in renal function, n (%) 6 (1.5) 3 (2.2) 1 (0.9) 2 (1.3) 0.664
Abnormal aPTT,a n (%) 8 (2.0) 0 (0.0) 3 (2.7) 5 (3.2) 0.124
Start  of dual antiplatelet therapy, n (%) 2 (0.5) 1 (0.7) 0 (0.0) 1 (0.6) 0.675
Others, n (%) 16 (4.0) 6 (4.4) 3 (2.7) 7 (4.5) 0.716
With  scheduled temporary use, n (%) 108 (26.7) 31 (23.0) 48 (42.9) 29 (18.5) <0.001
After  catheter ablation, n (%) 69 (17.1) 15 (11.1) 32 (28.6) 22 (14.0) <0.001
After  chemical cardioversion, n (%) 21 (5.2) 7 (5.2) 10 (8.9) 4 (2.5) 0.067
After  electrical cardioversion, n (%) 13 (3.2) 5 (3.7) 6 (5.4) 2 (1.3) 0.161
After  noncardiac operation, n (%) 6 (1.5) 5 (3.7) 0 (0.0) 1 (0.6) 0.030
Categorical and consecutive data are presented as number (%) and mean ± standard deviation, respectively. Percentages of adverse events (thromboembolic events, side
effects, and discontinuation) are presented as ratios of the number of events and patients.
aPTT, activated partial thromboplastin time.
a Abnormal aPTT included seven markedly elevated aPTT and one nonelevated aPTT (in phase III).
 Cardi
a
a
t
D
M
t
l
a
g
t
C
i
I
d
q
i
a
o
f
e
r
p
a
C
a
d
d
b
i
i
s
w
u
t
i
p
p
H
s
i
w
b
t
s
t
T
p
r
a
r
L
w
p
i
r
w
RS. Suzuki et al. / Journal of
nd was noticeably lower in phase II (8.0%). Discontinuation due to
n abnormal aPTT was observed in phases II and III, but was  limited
o a minority of patients (2.7% and 3.2%, respectively).
iscussion
ajor ﬁndings
We  studied the changes in attending physicians’ attitudes
oward the prescription of dabigatran for patients with nonva-
vular AF in a cardiovascular hospital before (phase I) and after
 blue letter (phases II and III). First, we found increasingly
uarded attitudes of attending physicians in phase II. Dabigatran
ended to be prescribed to patients with a lower age and higher
Cr and for those with less co-administration of p-glycoprotein
nhibitors or antiplatelet drugs in phase II compared with phase
. In addition, in phase II, we saw frequent short-term use of
abigatran followed by a scheduled discontinuation. The fre-
uency of aPTT measurement in patients taking dabigatran also
ncreased. Second, patient backgrounds under dabigatran ther-
py appeared to be partially expanded in phase III. The number
f patients with an older age, lower CCr, and presence of heart
ailure tended to increase in phase III compared with phase II. How-
ver, attending physicians continued a workaround for bleeding
isks with dabigatran in phase III by avoiding co-administration of
-glycoprotein inhibitors or antiplatelet drugs and by measuring
PTT.
hanges in attending physicians’ attitudes
The direct thrombin-inhibitor dabigatran is the ﬁrst to receive
pproval in Japan for stroke prophylaxis in AF. Because of the pre-
ictable pharmacokinetic and pharmacodynamic proﬁles of the
rug, routine monitoring of patients receiving dabigatran has not
een considered necessary [23]. New oral anticoagulants includ-
ng dabigatran were expected to simplify treatment paradigms and
mprove clinical outcomes [24,25]. In large trials, the efﬁcacy and
afety of dabigatran was  shown to be comparable or superior to
arfarin, even without routine monitoring of plasma levels or the
se of coagulation assays [26,27]. However, despite this informa-
ion, dabigatran was begun in a relatively guarded manner in our
nstitute; it was used for low CHADS2 (0–1 points) in 70% of our
atients, and aPTT was measured in ≥60% of our patients during
hase I.
A blue letter on dabigatran was issued by the Ministry of
ealth, Labour and Welfare in Japan in August 2011 [7]. This
afety alarm reported ﬁve fatal cases with severe bleeding. Sim-
lar to safety alarms in other countries [8–14], most of the cases
ith severe bleeding included patients with an older age, lower
ody weight, and a low CCr, and some were cases with a con-
raindication regarding renal function. How to respond to such
afety alarms has been much discussed worldwide, and the solu-
ions are of two types: “evidence-based” and “individualized” [17].
he former recommends avoiding prescriptions of dabigatran in
atients with high bleeding risks, including older age (≥75 years),
enal dysfunction (<50 ml/min/m2), high CHADS2 score, use of
ntiplatelet medications, and coexisting bleeding diseases. These
ecommendations were identiﬁed in the sub-analyses of the RE-
Y study [28,29], which were published just after the blue letter
as announced. In our institute, the prescription of dabigatran to
atients with older age, renal dysfunction, use of p-glycoprotein
nhibitors, and antiplatelet medications were either signiﬁcantly
educed or tended to be reduced in phase II, suggesting that these
ere evidence-based alterations affected by the sub-analyses of
E-LY [28,29].ology 62 (2013) 366–373 371
However, we pursued another solution to avoid bleeding risks
by individualizing [17] and stratifying the bleeding risk of patients
under dabigatran according to their individual responses using
laboratory testing, including aPTT [30–32]. We  found that the
responses of aPTT under dabigatran therapy were widely dis-
tributed irrespective of the dose of dabigatran and the timing of
blood sampling [22]. Although aPTT has limited sensitivity and is
not suitable for precise quantiﬁcation of the anticoagulant effect,
it is now widely recognized that aPTT may  be useful in deter-
mining an excess of anticoagulant activity [19]. In this regard, we
can distinguish high-risk patients with high aPTT from patients
with normal aPTT response. In our institute, prescription of dabiga-
tran for patients with older age (≥70 years) and renal dysfunction
(<50 ml/min/m2) tended to increase in phase III, which goes against
the evidence-based assumption [28,29]. Notably, other ﬁndings
were observed in phase III: the use of antiplatelet medications or
p-glycoprotein inhibitors decreased steadily or did not increase in
phase III, and the sampling rate of aPTT under dabigatran reached
approximately 100% in phase III. Therefore, we  can assume that
the attending physicians felt that they could start dabigatran for
patients with older age or renal dysfunction if they did not have
plural bleeding risks other than age and renal function, with the
ﬁnal judgment determined by the aPTT response under dabiga-
tran use. aPTT monitoring in patients at high risk of bleeding
(older age, renal dysfunction, use of antiplatelet medications or
p-glycoprotein inhibitors, or bleeding diseases) is partially recom-
mended in several recent guidelines [19,33]. However, aPTT-based
discontinuation was  observed infrequently (∼3%) in our insti-
tute.
Apart from the bleeding risks of the patients, the trend of throm-
boembolic risks was stable during the three phases in our study.
Approximately 70% of patients with AF under dabigatran ther-
apy were at a low or moderate risk for thromboembolism with a
CHADS2 score of 0–1, which did not change before and after the
blue letter or with permission for longer-term prescriptions. The
prevalence of a CHADS2 score of 0–1 in our study was much higher
than in patients with AF under warfarin therapy in a large Japanese
registry (J-RHYTHM registry, 47.2%) [6], but similar to the total
patients with AF in a nationwide registered cohort in a random-
ized controlled trial in Japan (J-RHYTHM study, 78.1%) [34]. The
trends of attending physicians’ attitudes in our study to start dabi-
gatran for low- or moderate-risk patients with AF may  have been
affected by the recent concept of net clinical beneﬁt. Although the
net clinical beneﬁt of warfarin (calculated as the rate of stroke pre-
vented by warfarin relative to the rate of intracranial hemorrhage
attributable to warfarin) was  signiﬁcantly high only in patients with
a CHADS2 score of ≥2 points [35], that for dabigatran was signiﬁ-
cantly high in patients at all CHADS2 risk levels with the exception
of the combined category of patients with a CHADS2 score of 0
points and a HAS-BLED score of ≥3 points [36]. The guarded trends
of attending physicians in our study were also supported by the
recently developed CHA2DS2-VASc risk score, which identiﬁes AF
patients indicated for anticoagulation therapy even in low CHADS2
score [37]. Such a low thromboembolic risk is known to be inher-
ently linked to a low bleeding risk under anticoagulation therapy
[38,39].
Patient outcomes
We observed several different patient outcomes, including
side effects, adverse events, and discontinuations. However, irre-
spective of the obvious changes in physicians’ attitudes toward
dabigatran therapy, we did not ﬁnd signiﬁcant improvement
in patient outcomes in terms of trends of time phases. First,
although frequent discontinuations of dabigatran were observed
in our institute throughout all three phases, this appeared to
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eﬂect the frequent temporary use of dabigatran before and after
atheter ablation or cardioversion, especially in phase II. How-
ver, this trend was suppressed in phase III, which may  have
een affected by the recent controversial discussion regarding
he efﬁcacy of the periprocedural use of dabigatran in catheter
blation [40–42]. Second, we found that the frequent inci-
ence of epigastric symptoms signiﬁcantly contributed to the
iscontinuation of dabigatran in all three phases. We  instruct
atients to drink a large cup of water when taking dabi-
atran, but it seems likely that epigastric symptoms remain
 signiﬁcant problem. Third, we found no signiﬁcant differ-
nce in adverse events, including thromboembolism and major
leeding, among the three phases. However, we cannot discuss
he differences among the three phases because of the small
umbers of events and the imbalanced and short observation peri-
ds.
tudy limitations
We  recognized several limitations in the present study. First,
n the present study, the true causes of alterations with dabiga-
ran prescription (i.e. increase and decrease in phases II and III)
ere not veriﬁed scientiﬁcally. Although our discussion directed
o indicate the relationship between aPTT measurement and the
xpansion of dabigatran prescription in phase III, the increase and
xpansion of dabigatran prescription in phase III may  be strongly
ffected by the permission of longer-term prescription itself, and it
ight be possibly linked to the remarkable increase of prescription
y non-arrhythmia specialists (as shown in Table 1). Also, although
ur discussion directed to indicate the relationship between the
lue letter and the decrease in dabigatran prescription in phase II,
he decrease and contraction of dabigatran prescription in phase II
ight accidentally coincide with the trough of the prescription rate
f dabigatran between the launch and the longer-term prescription.
o discriminate the factors which truly affected the phenomenon,
e need whole data of patients with nonvalvular AF who are at risk
or thromboembolism during the study periods (including those
ith other anticoagulants or without any anticoagulant therapy),
hich were lacking in our data. Second, although we described
hanges in attending physicians’ attitudes toward the prescrip-
ion of dabigatran, we found no signiﬁcant differences in patient
utcomes among the three time phases. This result was presum-
bly due to differences in patient backgrounds in each phase, the
mall number of events, and the short and imbalanced observation
eriods. In this regard, further investigation is needed. Third, our
ata comprised clinical records of a single specialized hospital for
ardiovascular care in an urban area in Japan. Therefore, the data
annot be extrapolated to other areas in Japan or other countries,
nd to general hospitals. Therefore, nationwide multicenter studies
ill be mandatory.
onclusions
We  described the changes in the attitudes of attending physi-
ians toward dabigatran prescription after the blue letter in a
pecialized hospital for cardiovascular care in Japan, which, we
elieve, involves useful information for safe use of dabigatran in
 real-world clinical setting. However, the true impact or effect of
he blue letter should be ascertained in a nationwide, multicenter
tudy.isclosures
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